Pieris appoints new Chief Executive Officer

Freising-Weihenstephan, Germany (ots) - Pieris Proteolab AG
announced today the appointment with immediate effect of Evert
Küppers (37) as its new Chief Executive Officer.

Mr Küppers joins Pieris from IDEA AG, where he was Vice President
and Head of Business Development. He played a pivotal role in the
company's corporate development by securing the Johnson & Johnson
partnership for its lead late stage clinical product. Prior to IDEA
he worked in London, United Kingdom, for the global pharmaceutical /
health care practice of AT Kearney, a management consultancy firm. Mr
Küppers acquired extensive operational experience during his four
year tenure at BASF Pharma (now Abbott Labs.) for whom he also spent
two years in Buenos Aires, Argentina, facilitating the establishment
of its local businesses.

Mr Küppers has a background in advanced biomedical sciences,
having obtained extensive molecular biology research experience in
the USA and The Netherlands, and an MBA degree from the Rotterdam
School of Management, Erasmus University Rotterdam, The Netherlands.

"We are extremely pleased that Evert Küppers has accepted this
position at Pieris" commented Dr Hans Küpper, Chairman of the
Supervisory Board. "The company is in an exciting phase, where
especially the experiences and hands-on skills of Mr Küppers are seen
as very complementary."

Evert Küppers, as appointed CEO, commented: "I am delighted to join
Pieris at such an interesting time. The industry is increasingly
appreciating the uniqueness of Pieris' proprietary ANTICALIN®
technology, as illustrated by our ongoing partnership with Syngenta
and our recently signed collaboration with GE Healthcare".

ENDS

For further information, please contact:

PIERIS Proteolab AG
Evert Küppers, Chief Executive Officer, Phone: +49 (0) 8161 1411
400

Notes to editors:

About Pieris Proteolab AG

Pieris, located just outside of Munich, Germany, is a
biopharmaceutical company focused on developing innovative ANTICALIN®
therapies for oncology, immunology and cardiovascular diseases.
Exploiting extensive know-how in protein engineering as part of a
broad intellectual property portfolio, the Company applies a balanced
risk business model to the development of its ANTICALIN® candidates.
Recognising the enormous market potential of protein-based drugs,
Pieris is creating the infrastructure of a drug discovery and
development company and expects to submit its first therapeutic
ANTICALIN® IND in 2007.

For further corporate information please visit
http://www.pieris.biz

ANTICALIN, ANTICALINS, PIERIS Proteolab, and the company's logo
are registered trademarks of PIERIS Proteolab AG.

Originaltext: Pieris ProteoLab AG
digital press kits: http://presseportal.de/story.htx?firmaid=61954
press kits via RSS: feed://presseportal.de/rss/pm_61954.rss2

Pressekontakt:
PIERIS Proteolab AG
Evert Küppers, Chief Executive Officer, Phone: +49 (0) 8161 1411 400